For research use only. Not for therapeutic Use.
HTH-02-006 is a NUAK2 inhibitor (IC50?=?126?nM). HTH-02-006 reduces levels of phosphorylated MYPT1 in HuCCT-1 cells. HTH-02-006 inhibits YAP-driven cell proliferation, hepatomegaly and tumorigenesis. HTH-02-006 also has antifibrotic protective effect[1][2].
| Catalog Number | I028920 |
| Synonyms | N-[3-[5-iodo-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]propanamide |
| Molecular Formula | C25H29IN6O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H29IN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h5-9,14-16H,4,10-13H2,1-3H3,(H,28,33)(H,27,29,30) |
| InChIKey | KQMWYEJQANQTDM-UHFFFAOYSA-N |
| SMILES | CCC(=O)NC1=CC(=CC=C1)OC2=NC(=NC=C2I)NC3=C(C=C(C=C3)N4CCN(CC4)C)OC |
| Reference | [1]. Yuan WC, et al. NUAK2 is a critical YAP target in liver cancer. Nat Commun. 2018 Nov 16;9(1):4834. [2]. Zhang T, et al. NUAK1 promotes organ fibrosis via YAP and TGF-β/SMAD signaling. Sci Transl Med. 2022 Mar 23;14(637):eaaz4028. |
